vs
ENERPAC TOOL GROUP CORP（EPAC）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是ENERPAC TOOL GROUP CORP的1.4倍（$207.3M vs $144.2M），ENERPAC TOOL GROUP CORP净利率更高（13.3% vs -62.0%，领先75.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -0.7%），ENERPAC TOOL GROUP CORP自由现金流更多（$13.3M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 2.1%）
恩派克工具集团前身为Actuant公司，成立于1910年，总部位于美国威斯康星州梅诺莫尼福尔斯，是一家历史悠久的工业工具企业，其普通股在纽约证券交易所上市，股票代码为EPAC。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
EPAC vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $144.2M | $207.3M |
| 净利润 | $19.1M | $-128.6M |
| 毛利率 | 50.7% | — |
| 营业利润率 | 19.8% | -54.7% |
| 净利率 | 13.3% | -62.0% |
| 营收同比 | -0.7% | 25.9% |
| 净利润同比 | -11.9% | 3.5% |
| 每股收益（稀释后） | $0.36 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $144.2M | $207.3M | ||
| Q3 25 | $167.5M | $159.9M | ||
| Q2 25 | $158.7M | $166.5M | ||
| Q1 25 | $145.5M | $139.3M | ||
| Q4 24 | $145.2M | $164.6M | ||
| Q3 24 | $158.7M | $139.5M | ||
| Q2 24 | $150.4M | $147.0M | ||
| Q1 24 | $138.4M | $108.8M |
| Q4 25 | $19.1M | $-128.6M | ||
| Q3 25 | $28.1M | $-180.4M | ||
| Q2 25 | $22.0M | $-115.0M | ||
| Q1 25 | $20.9M | $-151.1M | ||
| Q4 24 | $21.7M | $-133.2M | ||
| Q3 24 | $24.4M | $-133.5M | ||
| Q2 24 | $25.8M | $-131.6M | ||
| Q1 24 | $17.8M | $-170.7M |
| Q4 25 | 50.7% | — | ||
| Q3 25 | 50.1% | — | ||
| Q2 25 | 50.4% | — | ||
| Q1 25 | 50.5% | — | ||
| Q4 24 | 51.4% | — | ||
| Q3 24 | 48.8% | — | ||
| Q2 24 | 51.8% | — | ||
| Q1 24 | 51.6% | — |
| Q4 25 | 19.8% | -54.7% | ||
| Q3 25 | 23.8% | -106.9% | ||
| Q2 25 | 20.0% | -64.8% | ||
| Q1 25 | 21.2% | -102.6% | ||
| Q4 24 | 21.4% | -74.3% | ||
| Q3 24 | 18.9% | -94.6% | ||
| Q2 24 | 22.2% | -79.1% | ||
| Q1 24 | 21.3% | -151.9% |
| Q4 25 | 13.3% | -62.0% | ||
| Q3 25 | 16.8% | -112.8% | ||
| Q2 25 | 13.9% | -69.0% | ||
| Q1 25 | 14.4% | -108.5% | ||
| Q4 24 | 15.0% | -80.9% | ||
| Q3 24 | 15.4% | -95.7% | ||
| Q2 24 | 17.1% | -89.5% | ||
| Q1 24 | 12.9% | -156.8% |
| Q4 25 | $0.36 | $-1.28 | ||
| Q3 25 | $0.51 | $-1.81 | ||
| Q2 25 | $0.41 | $-1.17 | ||
| Q1 25 | $0.38 | $-1.57 | ||
| Q4 24 | $0.40 | $-1.34 | ||
| Q3 24 | $0.44 | $-1.40 | ||
| Q2 24 | $0.47 | $-1.52 | ||
| Q1 24 | $0.33 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $139.0M | $421.0M |
| 总债务越低越好 | $188.8M | — |
| 股东权益账面价值 | $431.1M | $-80.0M |
| 总资产 | $818.1M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
| Q4 25 | $139.0M | $421.0M | ||
| Q3 25 | $151.6M | $202.5M | ||
| Q2 25 | $140.5M | $176.3M | ||
| Q1 25 | $119.5M | $127.1M | ||
| Q4 24 | $130.7M | $174.0M | ||
| Q3 24 | $167.1M | $150.6M | ||
| Q2 24 | $132.4M | $480.7M | ||
| Q1 24 | $153.7M | $112.3M |
| Q4 25 | $188.8M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $191.3M | — | ||
| Q1 25 | $192.5M | — | ||
| Q4 24 | $193.8M | — | ||
| Q3 24 | $195.0M | — | ||
| Q2 24 | $196.3M | — | ||
| Q1 24 | $245.5M | — |
| Q4 25 | $431.1M | $-80.0M | ||
| Q3 25 | $433.7M | $9.2M | ||
| Q2 25 | $438.2M | $151.3M | ||
| Q1 25 | $406.0M | $144.2M | ||
| Q4 24 | $398.0M | $255.0M | ||
| Q3 24 | $392.0M | $346.8M | ||
| Q2 24 | $365.8M | $432.4M | ||
| Q1 24 | $336.9M | $140.3M |
| Q4 25 | $818.1M | $1.5B | ||
| Q3 25 | $827.9M | $1.2B | ||
| Q2 25 | $828.1M | $1.3B | ||
| Q1 25 | $776.6M | $1.3B | ||
| Q4 24 | $775.4M | $1.5B | ||
| Q3 24 | $777.3M | $1.5B | ||
| Q2 24 | $749.5M | $1.6B | ||
| Q1 24 | $769.3M | $1.3B |
| Q4 25 | 0.44× | — | ||
| Q3 25 | 0.44× | — | ||
| Q2 25 | 0.44× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.49× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 0.73× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $16.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $13.3M | $-100.8M |
| 自由现金流率自由现金流/营收 | 9.2% | -48.6% |
| 资本支出强度资本支出/营收 | 1.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.84× | — |
| 过去12个月自由现金流最近4个季度 | $102.5M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $16.0M | $-99.8M | ||
| Q3 25 | $55.3M | $-91.4M | ||
| Q2 25 | $39.9M | $-108.3M | ||
| Q1 25 | $7.5M | $-166.5M | ||
| Q4 24 | $8.6M | $-79.3M | ||
| Q3 24 | $44.4M | $-67.0M | ||
| Q2 24 | $30.3M | $-77.0M | ||
| Q1 24 | $13.3M | $-190.7M |
| Q4 25 | $13.3M | $-100.8M | ||
| Q3 25 | $52.3M | $-92.7M | ||
| Q2 25 | $35.1M | $-110.7M | ||
| Q1 25 | $1.8M | $-167.8M | ||
| Q4 24 | $2.8M | $-79.5M | ||
| Q3 24 | $37.9M | $-68.6M | ||
| Q2 24 | $28.5M | $-79.0M | ||
| Q1 24 | $11.7M | $-193.9M |
| Q4 25 | 9.2% | -48.6% | ||
| Q3 25 | 31.2% | -58.0% | ||
| Q2 25 | 22.1% | -66.5% | ||
| Q1 25 | 1.2% | -120.5% | ||
| Q4 24 | 1.9% | -48.3% | ||
| Q3 24 | 23.9% | -49.2% | ||
| Q2 24 | 18.9% | -53.7% | ||
| Q1 24 | 8.5% | -178.2% |
| Q4 25 | 1.9% | 0.5% | ||
| Q3 25 | 1.8% | 0.8% | ||
| Q2 25 | 3.1% | 1.5% | ||
| Q1 25 | 3.9% | 1.0% | ||
| Q4 24 | 4.0% | 0.1% | ||
| Q3 24 | 4.1% | 1.2% | ||
| Q2 24 | 1.2% | 1.4% | ||
| Q1 24 | 1.1% | 3.0% |
| Q4 25 | 0.84× | — | ||
| Q3 25 | 1.97× | — | ||
| Q2 25 | 1.81× | — | ||
| Q1 25 | 0.36× | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | 1.18× | — | ||
| Q1 24 | 0.75× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EPAC
| Transferred At Point In Time | $126.0M | 87% |
| Other | $12.1M | 8% |
| Other Operating Segment | $6.1M | 4% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
